share_log

Wells Fargo Maintains Overweight on Vertex Pharmaceuticals, Lowers Price Target to $460

Benzinga ·  Jan 10 08:12  · Ratings

Wells Fargo analyst Mohit Bansal maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Overweight and lowers the price target from $555 to $460.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment